Assistant Professor of Surgery, University Tex Houston
Thoracic Surgery
Dr. Wayne L. Hofstetter, MD
|
|
Give Review
Wayne Hofstetter is an expert in the field of Thoracic Surgery. He studied medicine at Keck School of Medicine of USC. Keck School of Medicine of USC has a rank of 31 in research and a 72 in primary care He received 1 awards: "Regional Top Doctor". Wayne L. Hofstetter is a published MD. He published 94 publications, including: 'Preoperative Chemoradiation Therapy vs Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiothera...' Wayne L. Hofstetter is registered with Medicare and accepts Medicare payments.
Publications
- Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
- Preoperative Chemoradiation Therapy vs Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiothera...
- Long-Term Survival in Patients with GastroEsophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
- Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small-Cell Lung Cancer.
- Endoscopic Ultrasound Estimates for Tumor Depth at the GastroEsophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection.
- The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in Esophageal cancer.
- RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung Cancer.
- Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.
- A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for Esophageal cancer.
- Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal Adenocarcinoma.
- Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung Cancer.
- International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).
- Limitations of 18F-2-Deoxy-d-Glucose Positron Emission Tomography in N1 Detection in Patients With Pathologic Stage II-N1 and Implications for Management.
- A validated miRNA profile predicts response to therapy in Esophageal adenocarcinoma.
- Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380.
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
- Impact of a Fast-Track Esophagectomy Protocol on Esophageal Cancer Patient Outcomes and Hospital Charges.
- Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer.
- Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role?
- Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation.
- Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to Esophageal cancer cells.
- Reply to R. Gertler et al.
- Influence of preoperative radiation field on postoperative leak rates in Esophageal cancer patients after trimodality therapy.
- Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
- Prediction of survival in resected non-small cell lung Cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy.
- Endoscopic Management of Barrett's Esophagus with High-Grade Dysplasia and Early-Stage Esophageal Adenocarcinoma.
- Evolving therapies in Esophageal carcinoma.
- IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non-Small Cell Lung Cancer Cells.
- Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer.
- Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies.
- ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable Esophageal cancer patients.
- Concordance of studies for nodal staging is prognostic for worse survival in Esophageal cancer.
- Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or GastroEsophageal Cancer: Implications for Screening and Surveillance.
- The Influence of Histopathologic Tumor Viability on Long-term Survival and Recurrence Rates Following Neoadjuvant Therapy for Esophageal Adenocarcinoma.
- Predictors of postoperative complications after trimodality therapy for Esophageal cancer.
- Evaluation of the reliability of clinical staging of t2 n0 Esophageal cancer: a review of the society of thoracic surgeons database.
- The society of thoracic surgeons guidelines on the diagnosis and staging of patients with Esophageal cancer.
- Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation.
- Pretreatment Patient Comorbidity and Tobacco Use Increase Cost and Risk of Postoperative Complications After Esophagectomy at a High-Volume Cancer Center.
- Diaphragmatic Hernia After Esophagectomy in 440 Patients With Long-Term Follow-Up.
- Visceral pleural invasion is not predictive of survival in patients with lung Cancer and smaller tumor size.
- Multimodality imaging evaluation of Esophageal cancer: staging, therapy assessment, and complications.
- Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroEsophageal cancer: analysis ...
- Gastric Cancer, Version 2.2013.
- Surgery Is an Essential Component of Multimodality Therapy for Patients with Locally Advanced Esophageal Adenocarcinoma.
- Obesity and outcomes in patients treated with chemoradiotherapy for Esophageal carcinoma.
- Loss of TGF-? Adaptor ?2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma.
- Current and future options for treating Esophageal cancer: a paradigm shift toward organ-sparing therapies.
- Utilization of surgery in trimodality-eligible patients with locally advanced Esophageal adenocarcinoma in a nonprotocol setting.
- Diaphragmatic Hernia After Esophagectomy for Esophageal Malignancy.
- Predictors of Recurrent Pulmonary Metastases and Survival After Pulmonary Metastasectomy for Colorectal Cancer.
- Esophageal reconstruction with alternative conduits.
- Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with Esophageal cancer.
- Patients with high body mass index tend to have lower stage of Esophageal carcinoma at diagnosis.
- Salvage Esophagectomy After Failed Definitive Chemoradiation for Esophageal Adenocarcinoma.
- Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer.
- A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oEsophageal cancer.
- Proton Beam Therapy and Concurrent Chemotherapy for Esophageal Cancer.
- Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial Esophageal cancers: a systematic review and meta-analysis.
- Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?
- Barrett's esophagus: treatments of adenocarcinomas II.
- Esophageal and esophagogastric junction cancers.
- Update: modern approaches to the treatment of localized Esophageal cancer.
- Computed Tomography Findings Predicting Invasiveness of Thymoma.
- Celebrate or Calibrate? We Say Calibrate.
- Duplicated Muscularis Mucosae Invasion has Similar Risk of Lymph Node Metastasis and Recurrence-free Survival as Intramucosal Esophageal Adenocarcinoma.
- Combined Esophagectomy and Pancreaticoduodenectomy: Expanded Indication for Supercharged Jejunal Interposition.
- A Phase II Study of a Paclitaxel-based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporti...
- Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study.
- Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with Esophageal or gastroEsophageal junction ...
- Automated symptom alerts reduce postoperative symptom severity after Cancer surgery: a randomized controlled clinical trial.
- Combined modality therapy of cT2N0M0 Esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.
- Dysfunctional transforming growth factor-? signaling with constitutively active Notch signaling in Barrett's Esophageal adenocarcinoma.
- The Role of PKR/eIF2? Signaling Pathway in Prognosis of Non-Small Cell Lung Cancer.
- The influence of high body mass index on the prognosis of patients with Esophageal cancer after surgery as primary therapy.
- Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique.
- Tumors of the mediastinum and chest wall.
- Critical role of surgery in patients with gastroEsophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.
- Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and Esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.
- Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroEsophageal junction.
- KLF4 inhibition of lung Cancer cell invasion by suppression of SPARC expression.
- Optimum lymphadenectomy for Esophageal cancer.
- Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
- Tumors of the diaphragm.
- Association of age and survival in patients with gastroEsophageal cancer undergoing surgery with or without preoperative therapy.
- Impact of tumor length on long-term survival of pT1 Esophageal adenocarcinoma.
- Putative tumor-suppressive function of Kruppel-like factor 4 in primary Lung carcinoma.
- Application of the revised lung Cancer staging system (IASLC Staging Project) to a Cancer center population.
- Outcomes with Esophageal cancer radiation therapy.
- Patterns of care and locoregional treatment outcomes in older Esophageal cancer patients: The SEER-Medicare Cohort.
- The fallen one: the inferior parathyroid gland that descends into the mediastinum.
- MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
- Radiation modality use and cardiopulmonary mortality risk in elderly patients with Esophageal cancer.
Schools
Keck Sch Of Med Of The Usc
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Myocardial Perfusion Imaging
- Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair
- Chest CT (incl. Heart and Lungs)
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Aortic Aneurysm
- Aortic Ectasia
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiac Surgery
- Thoracic Surgery
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Southern California - LAC+USC Medical Center -
Keck School of Medicine of USC
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1790874360 | |
| NPPES Provider LastName | HOFSTETTER | |
| NPPES Provider FirstName | WAYNE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Thoracic Surgery | |
| Total Claim Count | 138.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 20.29 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790874360 |
| Last Name Of The Provider | HOFSTETTER |
| First Name Of The Provider | WAYNE |
| View All |
Similar Doctors
|
Dr. Philip A. Rascoe, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ara A. Vaporciyan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen G. Swisher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Boris Sepesi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John E. Fetter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Garrett L. Walsh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Hazim J. Safi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony L. Estrera, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Adel D. Irani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jim S. Garza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dewei Ren, MD
This Doctor is OpenDoctor Recommended.
|